 Sio Gene Therapies Inc NASDAQ: SIOX has dosed the first patient in Phase 12 trial evaluating AXO-AAV-GM2 investigational gene therapy to treat GM2 gangliosidosis, also known as Tay-Sachs or Sandhoff disease, a rare genetic disorder that progressively destroys nerve cells in the brain and spinal cord. 